Navigation Links
Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
Date:7/31/2013

loped for treatment of inhalational anthrax. ETI-204 is formulated as a solution and is being evaluated for intravenous (IV) and/or intramuscular (IM) administration.

ETI-204 efficacy and safety is being studied in animal models of inhalational anthrax and safety studies are being conducted with human volunteers. Three studies assessing pharmacokinetics and safety of intravenous (IV) administration of ETI-204 in humans have been completed. The more common adverse events related to ETI-204 administration across the three studies included upper respiratory tract infection, nausea, headache, nasal congestion and erythema. ETI-204 was granted Fast Track status and Orphan Drug Designation by the FDA. 

This program is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services (HHS) under Contract Nos. HHSO100201000026C and HHS0100201100034C.

About Elusys Therapeutics, Inc.
Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. Elusys has been engaged in the development of ETI-204, an anthrax biowarfare countermeasures since 2000. The company has received multiple grants and contracts totaling over $200 million to support the development of ETI-204 to protect people in the event of an anthrax attack. Today, ETI-204 has advanced to the final stages of development, and is closer to achieving the company's goals of receiving FDA licensure and becoming part of the Strategic National Stockpile. For more information, please visit www.elusys.com.

SAFE HARBOR STATEMENT

This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. This r
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
4. eCareSoft Releases eCS Cirrus™
5. AtheroNova Releases 2011 Financial Results
6. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
7. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
8. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
9. Happtique Releases Draft App Certification Program Standards For Public Comment
10. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
11. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 21, 2014   TRU-D SmartUVC LLC and ... superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at FIS 2014 ... Nov. 23 to 26 at Stand 23. The ... United Kingdom,s largest infection-related event of its ... to one of the leading events of its type throughout ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short story ... published as a tribute to his mentor Ray ... Story” category of the 2014 USA Best Book ... USA Book News, said this year’s contest yielded over ... & Schuster, Penguin, John Wiley & Sons, Houghton Mifflin ...
(Date:11/21/2014)... NY (PRWEB) November 20, 2014 The ... now available as an open access journal featuring the ... infrared fluorescent proteins to preserve photoresponsiveness in the retina ... Two-color fluorescent in situ hybridization using chromogenic substrates in ... for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
Breaking Biology Technology:TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3
... 2011 The current revision of two ... blood-related diseases must ensure the safety of patients and ... was a key message of a two-day conference, "Haematology ... Parliament and attended by doctors, researchers, parliamentarians, patients, organisations ...
... Sectra  (NASDAQ OMX Stockholm: SECT B) has ... NYSE: PHG). Philips will pay EUR 57.5 million in a ... operation today, September 1, 2011. "The deal ... continue our efforts and expand our business. In Medical Systems, ...
... Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced James Levine, ... upcoming conferences. Mr. Levine will present at ... on Monday, September 12, 2011.  The presentation is expected ...
Cached Biology Technology:Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2Sectra and Philips Complete Modality Transaction 2Sectra and Philips Complete Modality Transaction 3Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... professor Deborah Steinberg of the Virginia Institute of Marine Science ... aboard the research vessel Laurence M. Gould. The VIMS ... in the waters along the west coast of the Antarctic ... microscopic animals that form the base of the Antarctic food ...
... binding oxygen to metalloporphyrins is a vital process for ... bound to the metal complex is also important in ... these binding mechanisms, scientists use porphyrin rings with a ... or silver support surface with these substances. An ...
... The world,s oceans are under siege. Conservation biologists regularly ... bluefin tuna, swordfish and sharks. Lose enough of these top-line ... oceanic web of life may collapse. In a new ... the University of Washington used a group of marine creatures ...
Cached Biology News:VIMS team returns to Antarctic Peninsula 2VIMS team returns to Antarctic Peninsula 3Direct observation of carbon monoxide binding to metal-porphyrines 2Species loss tied to ecosystem collapse and recovery 2Species loss tied to ecosystem collapse and recovery 3